Publication / Source: Neuro Central
Authors: Sharon Salt, Editor
In line with our focus this month on ‘emerging techniques and approaches’, we’ve brought together a panel of experts to discuss emerging therapies in multiple sclerosis (MS) in a two-part discussion. How extensive is our current knowledge of the mechanisms behind MS? What are the primary targets for existing therapies and future treatments? How could MS therapies change in the next 10 years? We’ve also incorporated the questions that you wanted to ask our experts, including the use of hematopoietic stem cell transplantation (HSCT) as a treatment option and how adult stem cells fare in relation to other stem cell sources.
Bringing together insights from across research and the pharmaceutical industry, our experts are Rick Munschauer (MedDay Pharmaceuticals, MA, USA), Luke Lairson (The Scripps Research Institute, CA, USA) and Valentina Fossati (New York Stem Cell Foundation, NY, USA). Take a look at the first installment of this discussion below, which looks at the mechanisms, therapies and challenges involved in MS research.
You can also read Part II of the discussion, which delves deeper into the use of stem cells and future research priorities for MS.
How extensive is our knowledge of MS and its mechanisms at present?